Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Browsing publications by Rebecca Perrett

Newcastle AuthorsTitleYearFull text
Professor Ruth Plummer
Rebecca Perrett
Professor Hilary Calvert
A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor2007
Professor Hilary Calvert
Dr Fathi Azribi
Rebecca Perrett
Professor Ruth Plummer
Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR2007
Dr Graham Dark
Rebecca Perrett
Deconstructing the construction of a learning module on practice development2007
Professor Ruth Plummer
Dr Louise Li
Rebecca Perrett
Professor Hilary Calvert
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers2007
Dr Graham Dark
Rebecca Perrett
Practice development - Part 1: Developing a practice initiative in oncology and palliative care2007
Dr Graham Dark
Rebecca Perrett
Practice development - Part 2: evaluating a practice initiative2007
Dr Graham Dark
Rebecca Perrett
Using e-learning as a tool for multidisciplinary education2007
Professor Ruth Plummer
Rebecca Perrett
Professor Hilary Calvert
A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours2006
Professor Ruth Plummer
Dr Louise Li
Rebecca Perrett
Professor Hilary Calvert
Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumours with mutated EGFR2006
Professor Ruth Plummer
Rebecca Perrett
Professor Hilary Calvert
A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors2005